Metraipolis › archive › dc_eec91793d7dd

Selection and characterization of a broadly neutralizing class of HCV anti-E2 VH1-69 antibodies — Europe PMC PMID:40153382

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40153382
DOI
10.1371/journal.ppat.1012428
License (as archived)
CC0-1.0
Archived
2026-10-06T12:00:15.719Z
SHA-256 of the archived text
dc2575ebe789bf1c40683f518ce33581f0303e64e122841b4ea88d56129ef736
Stable URL of this page
https://metraipolis.com/documento/dc_eec91793d7dd

How to cite

Selection and characterization of a broadly neutralizing class of HCV anti-E2 VH1-69 antibodies — Europe PMC PMID:40153382 — Europe PMC (en), https://europepmc.org/article/MED/40153382 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_eec91793d7dd (Metraipolis archive dc_eec91793d7dd, sha256 dc2575ebe789bf1c40683f518ce33581f0303e64e122841b4ea88d56129ef736)
BibTeX
@misc{dceec91793d7dd,
  title = {Selection and characterization of a broadly neutralizing class of HCV anti-E2 VH1-69 antibodies — Europe PMC PMID:40153382},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40153382},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_eec91793d7dd; sha256 dc2575ebe789bf1c40683f518ce33581f0303e64e122841b4ea88d56129ef736},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/40153382. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Identification and characterization of antibody epitope targets on the hepatitis C virus (HCV) envelope proteins remain crucial for developing an effective vaccine. Building on prior research defining E1/E2 antibody epitope clustering, we screened a phage display library derived from a chronic HCV patient against detergent-extracted full-length E1/E2 from both the patient's acute-phase isolate (H77, genotype 1a) and a heterologous isolate (S52, genotype 3a). This approach yielded a panel of VH1-69 derived antibody fragments (Fabs) with similar characteristics. Interestingly, all members of the panel exhibited blocking activity against both antigenic region 2 and 3 (AR2 and AR3) in competition ELISAs, which contrasts with the behavior of most previously identified AR3-targeting antibodies. The VH1-69 derived binders had a high affinity for soluble E2 in both Fab and IgG formats, with dissociation constants in the low picomolar range. These Fab binders were broadly neutralizing against a panel of HCV cell culture viruses of genotype 1-6 with higher potency than the well-characterized reference Fab, AR3A. However, in the IgG format the antibodies had similar potency. These findings expand our understanding of potential targets for vaccine development by characterizing a panel of antibodies targeting an AR3 epitope also involving or occluding the back layer of E2. The broad neutralization and high affinity of these antibodies suggest a benefit to targeting both the back layer and the front layer of E2 in HCV vaccine designs to expand the repertoire of broadly neutralizing antibodies, thereby offering promise for the development of more effective preventive measures against this pervasive human pathogen.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PLoS pathogens, 2025 (prima pubblicazione 2025-03-28).
Identificativi: PMID 40153382 · PMCID PMC11999149 · DOI 10.1371/journal.ppat.1012428.
Descrittori MeSH principali: Hepacivirus; Viral Envelope Proteins; Hepatitis C Antibodies; Antibodies, Neutralizing.
Pagina: https://europepmc.org/article/MED/40153382 — https://doi.org/10.1371/journal.ppat.1012428. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-06T10:21:17.999Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.